Vergara D - Search Results

1

An SPR based immunoassay for the sensitive detection of the soluble epithelial marker E-cadherin.

Vergara D, Bianco M, Pagano R, Priore P, Lunetti P, Guerra F, Bettini S, Carallo S, Zizzari A, Pitotti E, Giotta L, Capobianco L, Bucci C, Valli L, Maffia M, Arima V, Gaballo A. Vergara D, et al. Nanomedicine. 2018 Oct;14(7):1963-1971. doi: 10.1016/j.nano.2018.05.018. Epub 2018 Jun 15. Nanomedicine. 2018. PMID: 29902526

2

Proteomic map of peripheral blood mononuclear cells.

Vergara D, Chiriacò F, Acierno R, Maffia M. Vergara D, et al. Proteomics. 2008 May;8(10):2045-51. doi: 10.1002/pmic.200700726. Proteomics. 2008. PMID: 18491318

3

PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: A pilot study on relation to clinical findings and brain atrophy.

De Masi R, Vergara D, Pasca S, Acierno R, Greco M, Spagnolo L, Blasi E, Sanapo F, Trianni G, Maffia M. De Masi R, et al. Among authors: vergara d. J Neuroimmunol. 2009 May 29;210(1-2):80-6. doi: 10.1016/j.jneuroim.2009.03.002. Epub 2009 Mar 29. J Neuroimmunol. 2009. PMID: 19329191

4

Ovarian cancer biomarkers: a focus on genomic and proteomic findings.

Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R, Marsigliante S, Maffia M, Lorusso V. Tinelli A, et al. Among authors: vergara d. Curr Genomics. 2007 Aug;8(5):335-42. doi: 10.2174/138920207782446142. Curr Genomics. 2007. PMID: 19384429 Free PMC article.

5

Biomechanical and proteomic analysis of INF- beta-treated astrocytes.

Vergara D, Martignago R, Leporatti S, Bonsegna S, Maruccio G, De Nuccio F, Santino A, Cingolani R, Nicolardi G, Maffia M, Rinaldi R. Vergara D, et al. Nanotechnology. 2009 Nov 11;20(45):455106. doi: 10.1088/0957-4484/20/45/455106. Epub 2009 Oct 16. Nanotechnology. 2009. PMID: 19834248

6

IFN-beta reverses the lipopolysaccharide-induced proteome modifications in treated astrocytes.

Vergara D, Martignago R, Bonsegna S, De Nuccio F, Santino A, Nicolardi G, Maffia M. Vergara D, et al. J Neuroimmunol. 2010 Apr 15;221(1-2):115-20. doi: 10.1016/j.jneuroim.2010.01.002. Epub 2010 Feb 8. J Neuroimmunol. 2010. PMID: 20116864

7

Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells.

Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, Giovinazzo G, Santino A, Storelli C, Maffia M. Vergara D, et al. Cancer Lett. 2011 Nov 1;310(1):1-8. doi: 10.1016/j.canlet.2011.04.009. Epub 2011 Jun 24. Cancer Lett. 2011. PMID: 21794976

8

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

Vergara D, Bellomo C, Zhang X, Vergaro V, Tinelli A, Lorusso V, Rinaldi R, Lvov YM, Leporatti S, Maffia M. Vergara D, et al. Nanomedicine. 2012 Aug;8(6):891-9. doi: 10.1016/j.nano.2011.10.014. Epub 2011 Nov 16. Nanomedicine. 2012. PMID: 22100754

9

Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells.

Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, Pieragostino D, Tinelli A, De Domenico S, Alberti S, Urbani A, Salzet M, Santino A, Maffia M. Vergara D, et al. Mol Biosyst. 2012 Apr;8(4):1078-87. doi: 10.1039/c2mb05486h. Epub 2012 Jan 10. Mol Biosyst. 2012. PMID: 22234583

10

The impact of proteomics in the understanding of the molecular basis of Paclitaxel-resistance in ovarian tumors.

Vergara D, Tinelli A, Iannone A, Maffia M. Vergara D, et al. Curr Cancer Drug Targets. 2012 Oct;12(8):987-97. doi: 10.2174/156800912803251171. Curr Cancer Drug Targets. 2012. PMID: 22515523 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters